CSBIO(SZ:300255) Xin Lang Cai Jing·2025-09-11 05:27Group 1 - The core viewpoint of the news is that Changshan Pharmaceutical has seen a significant increase in its stock price, with a rise of 5.36% to 49.90 CNY per share, and a total market capitalization of 45.861 billion CNY [1] - Changshan Pharmaceutical, established on September 28, 2000, and listed on August 19, 2011, specializes in the research, production, and sales of heparin series products, with its main business revenue composition being 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other sources [1] Group 2 - From the perspective of fund holdings, one fund under Bosera Fund has a significant position in Changshan Pharmaceutical, with the Bosera National Index 2000 ETF holding 1,400 shares, accounting for 0.55% of the fund's net value, ranking as the fifth-largest holding [2] - The Bosera National Index 2000 ETF, established on November 23, 2023, has a latest scale of 11.7815 million CNY and has achieved a year-to-date return of 35.55%, ranking 834 out of 4,222 in its category [2] - The fund manager, Tang Yibing, has a tenure of 3 years and 53 days, with the fund's total asset scale at 9.874 billion CNY, achieving a best return of 86.4% and a worst return of -41.93% during his tenure [2]